[1]
|
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. DOI:10. 3322/caac. 20107. |
[2]
|
李鸣, 孙光, 贺大林, 等.前列腺癌诊断治疗指南[M].北京:人民卫生出版社, 2014:61-89.
Li M, Sun G, He DL, et al. The guide of diagnosis and treatment of prostate cancer[M]. Beijing:People′s Medical Publishing House, 2014:61-89. |
[3]
|
姚林, 周利群.前列腺癌的间歇性内分泌治疗[J].中华外科杂志, 2011, 49(2):176-179.
Yao L, Zhou LQ. The intermittent endocrine therapy of prostate cancer[J]. Chin J Surg, 2011, 49(2):176-179. |
[4]
|
Ghafoori M, Velayati M, Aliyari Ghasabeh M, et al. Prostate Biopsy Using Transrectal Ultrasonography; The Optimal Number of Cores Regarding Cancer Detection Rate and Complications[J/OL]. Iran J Radiol, 2015, 12(2): e13257[2016-05-01]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457971. DOI: 10.5812/iranjradiol.13257. |
[5]
|
Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers[J]. J Nucl Med, 2008, 49 Suppl 2:S24-42. DOI:10. 2967/jnumed. 107. 047258. |
[6]
|
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter(GLUT) proteins in cancer[J]. J Cell Physiol, 2005, 202(3):654-662. doi: 10.1002/jcp.20166 |
[7]
|
Effert P, Beniers AJ, Tamimi Y, et al. Expression of glucose transporter 1(Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma[J]. Anticancer Res, 2004, 24(5A):3057-3063. |
[8]
|
Stewart GD, Gray K, Pennington CJ, et al. Analysis of hypoxia-associated gene expression in prostate cancer:lysyl oxidase and glucose transporter-1 expression correlate with Gleason score[J]. Oncol Rep, 2008, 20(6):1561-1567. |
[9]
|
吴敏, 赵红光, 李英华, 等. PET-CT在前列腺癌诊断中的应用现状和展望[J].中国实验诊断学, 2015, 19(3):513-516.
Wu M, Zhao HG, Li YH, et al. The present state and perspectives of PET-CT in the diagnosis of prostate cancer[J]. Chin J Lab Diagn, 2015, 19(3):513-516. |
[10]
|
Liu IJ, Zafar MB, Lai YH, et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer[J]. Urology, 2001, 57(1):108-111. |
[11]
|
von Mallek D, Backhaus B, Müller SC, et al. Technical limits of PET/CT with 18FDG in prostate cancer[J]. Aktuelle Urol, 2006, 37(3):218-221. DOI:10. 1055/s-2006-932129. |
[12]
|
Watanabe H, Kanematsu M, Kondo H, et al. Preoperative detection of prostate cancer:a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging[J]. J Magn Reson Imaging, 2010, 31(5):1151-1156. DOI:10. 1002/jmri. 22157. |
[13]
|
Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2003, 30(4):607-611. DOI:10. 1007/s00259-002-1104-y. |
[14]
|
Minamimoto R, Uemura H, Sano F, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level[J]. Ann Nucl Med, 2011, 25(1):21-27. DOI:10. 1007/s12149-010-0424-4. |
[15]
|
王治国, 郭佳, 石庆学, 等. 18F-FDG PET/CT在前列腺癌诊断中的应用价值[J].临床军医杂志, 2014, 42(4):409-411. DOI:10. 3969/j.issn. 1671-3826. 2014. 04. 26.
Wang ZG, Guo J, Shi QX, et al. Value of 18F-FDG PET/CT in diagnosis of prostate cancer[J]. Clin J Med Offic, 2014, 42(4):409-411. doi: 10.3969/j.issn.1671-3826.2014.04.26 |
[16]
|
Brown AM, Lindenberg ML, Sankineni S, et al. Does focal incidental F-FDG PET/CT uptake in the prostate have significance?[J]. Abdom Imaging, 2015, 40(8):3222-3229. DOI:10. 1007/s00261-015-0520-y. |
[17]
|
Beauregard JM, Blouin AC, Fradet V, et al. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy[J/OL]. Cancer Imaging, 2015, 15: 2[2016-05-01]. http://www. ncbi. nlm. nih. gov/pmc/articles/PMC4352558. DOI: 10.1186/s40644-015-0038-0. |
[18]
|
Jadvar H. Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET[J]. Nat Rev Urol, 2009, 6(6):317-323. doi: 10.1038/nrurol.2009.81 |
[19]
|
Jadvar H. Prostate cancer:PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline[J]. J Nucl Med, 2011, 52(1):81-89. DOI:10. 2967/jnumed. 110. 077941. |
[20]
|
陈雯, 姚稚明, 张建飞, 等.同期18F-FDG PET/CT及MRI对于前列腺癌的初步对照研究[J].临床和实验医学杂志, 2015, 14(18):1491-1494. DOI:10. 3969/j.issn. 1671-4695. 2015. 18. 002.
Chen W, Yao ZM, Zhang JF, et al. A primary comparative study of the concurrent 18F-FDG PET/CT and MRI for the prostate cancer[J]. J Clin Exp Med, 2015, 14(18):1491-1494. doi: 10.3969/j.issn.1671-4695.2015.18.002 |
[21]
|
李杨, 齐琳, 叶慧. 18F-脱氧葡萄糖正电子发射计算机断层显像CT检查在前列腺癌诊断和分期中的应用价值[J].中华泌尿外科杂志, 2011, 32(10):682-684. DOI:10. 3760/cma.j.issn. 1000-6702. 2011. 10. 013.
Li Y, Qi L, Ye H. Applications value of 18F-FDG PET/CT in the diagnosis and staging of prostate cancer[J]. Chin J Urol, 2011, 32(10):682-684. doi: 10.3760/cma.j.issn.1000-6702.2011.10.013 |
[22]
|
Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management:findings of the national oncologic PET registry[J]. J Nucl Med, 2008, 49(12):1928-1935. DOI:10. 2967/jnumed. 108. 056713. |
[23]
|
Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation[J]. Nucl Med Commun, 2001, 22(9):963-969. |
[24]
|
Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer[J]. Mol Imaging Biol, 2002, 4(1):99-104. |
[25]
|
Meirelles GS, Schöder H, Ravizzini GC, et al. Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer[J]. Clin Cancer Res, 2010, 16(24):6093-6099. DOI:10. 1158/1078-0432.CCR-10-1357. |
[26]
|
Jadvar H, Desai B, Ji L, et al, . Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer[J]. J Nucl Med, 2013, 54(8):1195-1201. DOI:10. 2967/jnumed. 112. 114116. |
[27]
|
Zukotynski KA, Kim CK, Gerbaudo VH, et al. 18F-FDG-PET/CT and 18F-NaF-PET/CT in men with castrate-resistant prostate cancer[J]. Am J Nucl Med Mol Imaging, 2015, 5(1):72-82. |
[28]
|
Yu CY, Desai B, Ji L, et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer:a critical analysis of literature[J]. Am J Nucl Med Mol Imaging, 2014, 4(6):580-601. |
[29]
|
Mapelli P, Panebianco V, Picchio M. Prostate cancer recurrence:can PSA guide imaging?[J]. Eur J Nucl Med Mol Imaging, 2015, 42(12):1781-1783. DOI:10. 1007/s00259-015-3091-9. |
[30]
|
Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer[J]. Urol Int, 2003, 70(4):311-315. DOI:10. 1159/000070141. |
[31]
|
Schöder H, Herrmann K, Gönen M, et al. 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy[J]. Clin Cancer Res, 2005, 11(13):4761-4769. doi: 10.1158/1078-0432.CCR-05-0249 |
[32]
|
Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer[J]. Clin Nucl Med, 2012, 37(7):637-643. DOI:10. 1097/RLU. 0b013e318252d829. |
[33]
|
徐慧琴, 薛杨央, 赵学峰, 等. 18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志, 2011, 35(2):81-84. DOI:10. 3760/cma.j.issn. 1673-4114. 2011. 02. 004.
Xu HQ, Xue YY, Zhao XF, et al. Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J]. Int J Radiat Med Nucl Med, 2011, 35(2):81-84. doi: 10.3760/cma.j.issn.1673-4114.2011.02.004 |
[34]
|
Pillarsetty N, Punzalan B, Larson SM. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer[J]. J Nucl Med, 2009, 50(10):1709-1714. DOI:10. 2967/jnumed. 109. 064212. |
[35]
|
Castellucci P, Jadvar H. PET/CT in prostate cancer:non-choline radiopharmaceuticals[J]. Q J Nucl Med Mol Imaging, 2012, 56(4):367-374. |
[36]
|
Yu CY, Desai B, Ji L, et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer:a critical analysis of literature[J]. Am J Nucl Med Mol Imaging, 2014, 4(6):580-601. |
[37]
|
Meirelles GS, Schöder H, Ravizzini GC, et al. Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer[J]. Clin Cancer Res, 2010, 16(24):6093-6099. DOI:10. 1158/1078-0432.CCR-10-1357. |